Beacon Pharmaceuticals PLC
Abemaciclib Cancer (oncology)
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Abeza | 150 mg and 200 mg tablets | — | — | — | — |
| Abeza | 150 mg | Tablet | BDT 950 | US$7.73 | 1 x 14: ৳ 13,300.00 |
| Abeza | 200 mg | Tablet | BDT 1,150 | US$9.36 | 1 x 14: ৳ 16,100.00 |
Adalimumab Immunology & rheumatology
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Adali | 40 mg/0.8 ml | SC Injection | — | — | — |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Barinez | 2 mg | Tablet | BDT 25 | US$0.20 | 1 x 15: ৳ 375.00 |
Bevacizumab Cancer (oncology)
Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Bevastim | 100 mg/4 mL (BDT 13,925) and 400 mg/16 mL (BDT 52,205) | — | — | — | — |
| Bevastim | 100 mg/4 ml | IV Infusion | — | — | — |
| Bevastim | 400 mg/16 ml | IV Infusion | — | — | — |
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Crizonix | 250 mg capsule | — | — | — | — |
| Alkriz | 250 mg capsule | — | — | — | — |
| Alkriz | 250 mg | Capsule | BDT 750 | US$6.10 | 7 x 4: ৳ 21,000.00 |
Dapagliflozin Diabetes & metabolic
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Dapawin | 5 mg | — | — | — | — |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Sinjard | 10 mg, 25 mg | — | — | — | — |
| Sinjard | 25 mg | Tablet | BDT 50 | US$0.41 | 2 x 7: ৳ 700.00 |
| Sinjard | 10 mg | Tablet | BDT 25 | US$0.20 | 4 x 7: ৳ 700.00 |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Ibrucon | 140 mg capsule | — | — | — | — |
| Ibrucon | 140 mg | Capsule | BDT 600 | US$4.88 | 4 x 6: ৳ 14,400.00 |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Glipxen | 5 mg tablet | — | — | — | — |
| Glipxen | 5 mg | Tablet | BDT 22 | US$0.18 | 4 x 7: ৳ 616.00 |
Lorlatinib Cancer (oncology)
Originator: Lorbrena · Pfizer Inc.
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Loranix | 100 mg tablet | — | — | — | — |
| Loranix | 100 mg | Tablet | BDT 1,660 | US$13.51 | 5 x 6: ৳ 49,800.00 |
Niraparib Cancer (oncology)
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Niraparix (also listed as Nirova on MedEx) | 100 mg capsule | — | — | — | — |
| Nirova | 100 mg | Capsule | BDT 1,095 | US$8.91 | 1 x 6: ৳ 6,570.00 |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Olapar | 100 mg (BDT 1,150) and 150 mg (BDT 1,700) tablets | — | — | — | — |
| Olapar | 100 mg | Tablet | BDT 1,150 | US$9.36 | 4 x 6: ৳ 27,600.00 |
| Olapar | 150 mg | Tablet | BDT 1,700 | US$13.84 | 7 x 4: ৳ 47,600.00 |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Ositag | 80 mg tablet | — | — | — | — |
| Ositag | 80 mg | Tablet | BDT 550 | US$4.48 | 3 x 10: ৳ 16,500.00 |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Palker (exported/marketed as Palbonix) | 125 mg capsule | — | — | — | — |
| Palker | 125 mg | Capsule | BDT 400 | US$3.26 | 1 x 21: ৳ 8,400.00 |
Rituximab Cancer (oncology)
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Rituxim | 10 mg/mL, 100 mg and 500 mg vials | — | — | — | — |
| Rituxim | 10 mg/ml | IV Infusion | — | — | — |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Fixvel; Sofosvel | 400 mg + 100 mg tablet | — | — | — | — |
| Fixvel | 400 mg+100 mg | Tablet | BDT 1,000 | US$8.14 | 1 x 6: ৳ 6,000.00 |
Sotorasib Cancer (oncology)
Originator: Lumakras · Amgen
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Sotoras | 120 mg | Tablet | BDT 1,500 | US$12.21 | 5 x 6: ৳ 45,000.00 |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Jaktor | 5 mg | Tablet | BDT 48 | US$0.39 | 3 x 10: ৳ 1,440.00 |
| Jaktor XR | 11 mg | Tablet (Extended Release) | BDT 75 | US$0.61 | 3 x 10: ৳ 2,250.00 |
| Tofacinix | 11 mg | Tablet (Extended Release) | BDT 75 | US$0.61 | 3 x 10: ৳ 2,250.00 |
Trastuzumab Cancer (oncology)
Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Trastunix | 440 mg/20 mL | — | — | — | — |
| Trastunix | 440 mg/20 ml | IV Infusion | — | — | — |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.